Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
OptimizeRx Corp
Bear Case (25th pct.)
-33.3% vs price
Base Case (Median)
-26.9% vs price
Bull Case (75th pct.)
-9.6% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $7.14 | -22.2% | High (40%) |
| PE Comparable | $6.27 | -31.6% | Medium (25%) |
| Graham Number | $6.07 | -33.8% | Low (10%) |
| EV/EBITDA | $8.68 | -5.4% | Medium (20%) |
| EV/FCF | $19.40 | 111.5% | Medium (20%) |
| Earnings Power Value | $3.85 | -58.0% | Medium (50%) |
Based on 6 out of 7 methods, OPRX appears overvalued at the current price of $9.17. The base case fair value of $6.70 implies 26.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.